qfx

Indeed, the signs of Nvidia’s enduring dominance are as clear as a London fog. The grandees of the investment world, those who have spent a lifetime parsing the fine print of financial alchemy, are now dipping their toes into the waters of its stock. Daniel Loeb of Third Point, that arch-contrarian, has embarked on a modest acquisition of Nvidia shares, a $442 million foray that, in the grand scheme of his fund, represents a 6% stake. A wager, one might say, with the air of a man who has just discovered a new and improbable sport.

Let’s cut through the corporate jargon and the boardroom incense: Target is a house of cards in a hurricane. Its Q2 2025 results? A 0.9% revenue drop, 1.2% same-store sales collapse. Meanwhile, Walmart is out there nuking its competitors with a 4.6% sales surge. Target’s “upscale” schtick? It’s a sinking ship with a first-class ticket to Nowhere, USA. The madness is palpable, the panic real. They’re selling overpriced organic kale to a public that’s just trying to survive inflation. 🌱

In the annals of a Reuters report, there emerged speculation that orforglipron, a nascent contender in the realm of obesity treatment, might find its way to the hallowed halls of the FDA’s approval before the year’s end. Though uncertainty lingers like a fog on a quiet morning, optimism permeated among those keeping watch over Eli Lilly’s fortunes.

The market’s enthusiasm was, to be fair, somewhat understandable. One announcement detailed a potential successor to Wegovy, the drug that’s turned obesity into a lucrative niche for the company. The other suggested that Wegovy might do more than just melt away pounds-it might also help people stop thinking about cake. (A development so profound it could rival the invention of the tea bag.)